摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-叔丁氧基羰基-1,4-TRANS-二氨基甲基环己烷 | 166168-16-7

中文名称
N-叔丁氧基羰基-1,4-TRANS-二氨基甲基环己烷
中文别名
反式-4-(叔丁氧羰基氨基甲基)环己基甲胺;1-(4-氨甲环己基)-1-N-BOC-甲胺;反式-4-(Boc-氨甲基)环己甲胺;反式-L-4-(Boc-氨基甲基)-环己烷甲胺
英文名称
N-Boc-trans-1,4-bis(aminomethyl)cyclohexane
英文别名
N-{[trans-4-(aminomethyl)cyclohexyl]methyl}(tert-butoxy)carboxamide;trans-(4-aminomethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester;tert-butyl ((1r,4r)-4-(aminomethyl)cyclohexyl)methylcarbamate;tert-butyl ((trans-4-(aminomethyl)cyclohexyl)methyl)carbamate;tert-butyl N-[[4-(aminomethyl)cyclohexyl]methyl]carbamate
N-叔丁氧基羰基-1,4-TRANS-二氨基甲基环己烷化学式
CAS
166168-16-7
化学式
C13H26N2O2
mdl
——
分子量
242.362
InChiKey
NYXOBVVHJZENCO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    358.5±15.0 °C(Predicted)
  • 密度:
    0.980±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.92
  • 拓扑面积:
    64.4
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 储存条件:
    存储温度应保持在0-5°C之间。

SDS

SDS:d2ab830490aabd9fa4c6f4bf57031ac6
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Trans-4-(boc-aminomethyl)-cyclohexanemethanamine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Trans-4-(boc-aminomethyl)-cyclohexanemethanamine
CAS number: 166168-16-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H26N2O2
Molecular weight: 242.4

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-叔丁氧基羰基-1,4-TRANS-二氨基甲基环己烷2,4-二氯-5 硝基嘧啶N,N-二异丙基乙胺 作用下, 以 乙腈 为溶剂, 以71%的产率得到trans-{4-[(2-chloro-5-nitro-pyrimidin-4-ylamino)-methyl]-cyclohexylmethyl}-carbamic acid tert-butyl ester
    参考文献:
    名称:
    WO2007/76247
    摘要:
    公开号:
  • 作为产物:
    描述:
    tert-butyl (4-cyanocyclohexyl)methylcarbamate 以95的产率得到N-叔丁氧基羰基-1,4-TRANS-二氨基甲基环己烷
    参考文献:
    名称:
    Heterocyclic Compounds
    摘要:
    本发明涉及公式如规范所示的杂环化合物。它还涉及使用其中一种杂环化合物治疗炎症性疾病或免疫性疾病、发育或退化性疾病以及组织损伤的方法。
    公开号:
    US20090264339A1
点击查看最新优质反应信息

文献信息

  • 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
    申请人:PAJOUHESH Hassan
    公开号:US20090298834A1
    公开(公告)日:2009-12-03
    Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing 4-(aminomethyl)cyclohexanamine derivatives as shown in formula (1).
    揭示了在改善以不需要的钙通道活性为特征的状况中有效的方法和化合物,特别是不需要的T型钙通道活性。具体来说,包含4-(氨甲基)环己胺衍生物的一系列化合物如公式(1)所示。
  • Synthesis of amino-protected cyclohexane-1,4-diyldimethanamine and its derivatives
    申请人:Yen Chi-Feng
    公开号:US20080242861A1
    公开(公告)日:2008-10-02
    This invention relates to methods of preparing the compounds of formula (V): Each variable in this formula is defined in the specification.
    这项发明涉及制备化合物的方法,其化学式为(V):该化学式中的每个变量在规范中有定义。
  • [EN] NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087<br/>[FR] NOUVEAUX INHIBITEURS DE L'ACÉTYL COENZYME A CARBOXYLASE (ACC) ET UTILISATIONS DANS LE TRAITEMENT DE L'OBÉSITÉ ET DU DIABÈTE SUCRÉ - 087
    申请人:ASTRAZENECA AB
    公开号:WO2009082346A1
    公开(公告)日:2009-07-02
    The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for th eir therapeutic use, particularly in the treatments of obesity and diabetes mellitus.
    本发明涉及根据式(I)的乙酰辅酶A羧化酶(ACC)抑制剂,或其对映体,或其药用可接受的盐,其中R1、R2、R3、R4、R5、E、L、Z和n的定义如本文所述,以及制备此类化合物的方法,含有它们的药物组合物,使用这种抑制剂以及用于它们的治疗用途的方法,特别是用于肥胖和糖尿病的治疗。
  • [EN] 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA<br/>[FR] DERIVES DE 2,4-DIAMINOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE L'ENZYME PKC-THETA
    申请人:BOEHRINGER INGELHEIM PHARMA
    公开号:WO2004067516A1
    公开(公告)日:2004-08-12
    Disclosed are novel compounds of formula (I) wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders and processes for preparing these compounds.
    揭示了一种新型的化合物,其化学式为(I),其中R1、R2和R3如本文所定义,这些化合物可作为PKC-theta的抑制剂,因此可用于治疗各种通过PKC-theta活性介导或维持的疾病和疾病,包括免疫性疾病和2型糖尿病。该发明还涉及包含这些化合物的药物组合物,使用这些化合物治疗各种疾病和疾病的方法以及制备这些化合物的过程。
  • [EN] NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS<br/>[FR] NOUVEAUX INDOLES ET DÉRIVÉS D'ISOINDOLINONE SUBSTITUÉS EN TANT QU'INHIBITEURS DE RAS
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2020173935A1
    公开(公告)日:2020-09-03
    -The present invention relates to new isoindolinone or isobenzofuranone substituted indoles and derivatives of formula (I) wherein the groups R1 to R7, R10 and n have the meanings given in the claims and specification, their use as inhibitors of RAS-family proteins and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    本发明涉及新的异吲哚酮或异苯并呋喃酮取代吲哚和公式(I)衍生物,其中基团R1至R7、R10和n具有权利要求和说明中给定的含义,它们作为RAS家族蛋白的抑制剂的用途以及它们作为药物的用途,特别是作为治疗和/或预防肿瘤疾病的药物。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物